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The 'boom' in complementary medicine The Research Council for Complementary Medicine (RCCM) welcomes some of the sentiments expressed by Professor Ernst in his editorial (May 1998 JRSM, pp 235-6). Therapies should be validated scientifically. Patients require reassurance that the treatments they receive are both effective and safe.
Ernst equates the 'boom' in complementary medicine with the herbal and food supplement market. There are concerns that need to be addressed in this area with regard to supplements and herbal remedies but it is incorrect to equate sales of remedies with usage patterns. In a sense the jury is still out on whether the upward trends in usage of complementary medicine have peaked.
Again when referring to the closure of complementary therapy centres, Ernst misleads the reader by presenting these as a result of lack of efficacy. There is some evidence that budgetary implications were the primary concern. Ernst rightly points out the broad definition of complementary medicine found in the Eisenberg study. To then make conclusions about declining usage patterns by referring to the Paramore study, which focused on only four treatment modalities, is again unhelpful and misleading.
What is required now is good quality unbiased research, improved research training for practitioners, familiarization for general practitioners and dissemination of reliable information to users. The RCCM is working in all these areas. Research may then lead to safe, effective practice Whatever the merits of factors VIII and IX now available, the fact remains that none provides replacement therapy for more than a short period; the half-life of transfused factors is 10-12 hours for factor VIII and 15-20 hours for factor IX in patients with haemophilia A or B, respectively. I have suggested that, in haemophilia, deficiency of coagulant factor VIII or IX may not be due to failed production, but rather to their inhibited release from tissues1. The implications of this proposal are of paramount importance in management of the disorder.
Normal genes for factors VIII and IX are expressed in tissue cells by production of the respective factor2. These factors are then transported across the cell membrane3 to be released into the plasma by a yet unidentified mechanism. A low level of plasma factor VIII or factor IX may therefore arise from defects either reducing intracellular production or inhibiting release of these factors into circulating plasma.
If the aminoacid sequence of the protein produced by the gene is known, the required DNA code can be worked out and made in the laboratory, or cut from the 4 entire genome by restriction enzymes4. Recombinant DNA, now in use, is based on the chemical composition of isolated plasma factor VIII or factor IX. Genes are expressed in tissues, not in plasma2,4, and several differences between plasma and tissue factors VIII and IX have been describeds. Furthermore, the genetic DNA codes for human tissue factors VIII and IX have yet to be determined. One cannot therefore categorically assert that recombinant DNA is an exact replica of the biological gene expressed by tissue factor production. Nor is synthesis of plasma factors VIII and IX in transgenic hosts indicative of reduced production of factor VIII or factor IX in haemophilia.
There is no denying that blood factors VIII and IX originate in the tissues. Normal content of factors VIII and IX activity is found in all tissues of haemophilic patients, in amniotic fluid surrounding a haemophilic fetus and in breast milk and saliva1'5 of haemophilia carriers. Thus, the fault in haemophilia A and haemophilia B seems to lie not in intracellular production of factor VIII or factor IX, but in their release into the blood plasma. Work is urgently required to identify the gene coding for the protein regulating the release of factor VIII and/or factor IX from the tissues. The respective DNA may then be inserted into an appropriate tissue 4 , giving long-term correction of the respective defect by restoring release of the corresponding plasma factor. Autogenous clotting factors VIII and IX would be free from all complications of isolated and genetically engineered factors, including circulating inhibitors. 
